InnoCare tafasitamab combo gets approval in Hong Kong for blood cancer subtype

Dec. 28, 2022 5:30 AM ETIncyte Corporation (INCY), MORBMY, MPSYFBy: Ravikash, SA News Editor

document with approved stamp on computer keyboard


InnoCare Pharma said tafasitamab in combination with lenalidomide, sold as Revlimid by Bristol-Myers Squibb (BMY), was approved in Hong Kong to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.